AnaptysBio, Inc. has authorized an amended Stock Repurchase Plan to repurchase up to $100 million of its outstanding common stock. The company anticipates ending 2025 with approximately $300 million in cash, including a $75 million milestone due from GSK. The shares may be repurchased in open market transactions, with the plan expiring on March 31, 2026. Anaptys focuses on delivering immunology therapeutics for autoimmune and inflammatory diseases and plans to separate its biopharma operations from its royalty assets by year-end 2026. The company’s forward-looking statements highlight risks and uncertainties related to its product candidates and financial goals.

Read more at GlobeNewswire: Anaptys Announces $100 Million Stock Repurchase Plan